

PRODUCT INFORMATION



AL 8810 methyl ester

Item No. 10008370

CAS Registry No.: 1176541-11-9
Formal Name: 9 α ,15R-dihydroxy-11 β -fluoro-15-(2,3-dihydro-1H-inden-2-yl)-16,17,18,19,20-pentanoic-prosta-5Z,13E-dien-1-oic acid, methyl ester

MF: C₂₅H₃₃FO₄


FW: 416.5

Purity: \geq 98%

Supplied as: A crystalline solid

Storage: 20°C

Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AL 8810 methyl ester is supplied as a crystalline solid. A stock solution may be made by dissolving the AL 8810 methyl ester in the solvent of choice, which should be purged with an inert gas. AL 8810 methyl ester is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of AL 8810 methyl ester in these solvents is approximately 50, 25, and 30 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of AL 8810 methyl ester can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of AL 8810 methyl ester in PBS (pH 7.2) is approximately 0.5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

AL 8810 is an 11 β -fluoro analog of prostaglandin F_{2 α} (PGF_{2 α}) which acts as a potent and selective antagonist at the FP receptor.¹ AL 8810 methyl ester is a lipid soluble, esterified prodrug form of AL 8810 analogous to the commonly used therapeutic intraocular PG compounds such as latanoprost and travoprost.^{2,3} The pharmacology of AL 8810 methyl ester has not been published.

References

1. Griffen, B.W., Klimko, P., Crider, J.Y., *et al.* AL-8810: A novel prostaglandin F_{2 α} analog with selective antagonist effects at the prostaglandin F_{2 α} (FP) receptor. *J. Phar. Exp. Ther.* **290**, 1278-1284 (1999).
2. Camras, C.B., Alm, A., Watson, P., *et al.* Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. *Ophthalmology* **103**, 1916-1924 (1996).
3. Sorbera, L.A. and Castañer, J. Travoprost. *Drugs of the Future* **25**, 41-45 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/30/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM